从2026年到2027年, 特朗普政府利用国际基准削减成本, 推出《医保计划》药物定价试点。 
The Trump administration launches Medicare drug pricing pilots to cut costs using international benchmarks, starting in 2026–2027.
特朗普政府启动了两个新的医疗保险药品定价试点方案——GUARD和GLOBE——以降低处方药品费用,将美国价格与国际基准进行比较,并根据全球数据确定自付费用。 The Trump administration has launched two new Medicare drug pricing pilot programs—GUARD and GLOBE—to lower prescription drug costs by comparing U.S. prices to international benchmarks and setting out-of-pocket costs based on global data. 从2026年和2027年开始,这些方案将针对糖尿病和癌症等疾病的高成本药物,如果美国价格超过外国水平,可能给予退款。 Starting in 2026 and 2027, the programs will target high-cost drugs for conditions like diabetes and cancer, with potential rebates if U.S. prices exceed foreign levels. 这些举措是在与9家制药公司签订降低价格协议之后采取的。 These initiatives follow agreements with nine pharmaceutical companies to reduce prices. 与此同时,医疗补助的削减预计将减少联邦开支、紧缩资格、降低报销额和使数百万人面临保险损失的风险。 Meanwhile, Medicaid cuts are expected to reduce federal spending, tightening eligibility, lowering reimbursements, and risking coverage losses for millions. 供应商面临收入下降和合规风险增加,而卫生系统正在采用基于价值的护理和AI工具,以便在财政和业务压力下提高效率和患者获得服务的机会。 Providers face declining revenues and rising compliance risks, while health systems are adopting value-based care and AI tools to improve efficiency and patient access amid financial and operational pressures.
